Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The **allergenic extract of Betulaceae** is a standardized biologic product developed by the Italian pharmaceutical company **LOFARMA**. It is derived from the pollen of trees within the Betulaceae family, most notably birch (*Betula* species), and contains a complex mixture of allergenic proteins. The extract serves a dual purpose: it is used as a diagnostic reagent in skin prick testing (SPT) to identify sensitization in allergic individuals and as the active component in allergen immunotherapy (AIT) to treat respiratory allergies. Its mechanism of action involves the modulation of the IgE-mediated immune response; by interacting with allergen-specific IgE antibodies on mast cells and basophils, it can either trigger a diagnostic localized reaction or, through repeated therapeutic administration, induce long-term immune tolerance. The extract has been evaluated in Phase 2 clinical trials in Italy for biological standardization using histamine equivalent prick (HEP) units and the definition of in-house reference preparations (IHRP).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on allergenic extract of Betulaceae.